Shinya Maita

Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Demographic and Geographical Distribution of Dentists in Japan: Analysis of National Data in 1996, 2006, and 2016.

Demographic and Geographical Distribution of Dentists in Japan: Analysis of National Data in 1996, 2006, and 2016.

Journal: The Tohoku journal of experimental medicine

Published: July 01, 2026

Clinical Impact of Preoperative Obesity on Living-Donor Kidney Transplant Recipients in Japan: A Multicenter Experience.

Clinical Impact of Preoperative Obesity on Living-Donor Kidney Transplant Recipients in Japan: A Multicenter Experience.

Journal: Journal of clinical medicine

Published: December 14, 2025

Clinical outcomes of living kidney transplantation from donors aged 70 years and older: a Japanese multicenter study.

Clinical outcomes of living kidney transplantation from donors aged 70 years and older: a Japanese multicenter study.

Journal: Scientific reports

Published: October 09, 2025

Benefits of Preemptive Living Kidney Transplantation: Reduced Rates of Cerebro-Cardiovascular Events and Neoplasm Development.

Benefits of Preemptive Living Kidney Transplantation: Reduced Rates of Cerebro-Cardiovascular Events and Neoplasm Development.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: May 16, 2025

ABO-incompatible living-donor kidney transplantation is not associated with post-transplant malignancy: a multicenter retrospective study.

ABO-incompatible living-donor kidney transplantation is not associated with post-transplant malignancy: a multicenter retrospective study.

Journal: Clinical and experimental nephrology

Published: January 29, 2025

Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.

Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.

Journal: The Prostate

Published: July 03, 2024

Efficacy of valganciclovir prophylaxis in kidney transplant recipients following low-dose rituximab induction therapy: a multicenter retrospective study.

Efficacy of valganciclovir prophylaxis in kidney transplant recipients following low-dose rituximab induction therapy: a multicenter retrospective study.

Journal: Clinical and experimental nephrology

Published: June 25, 2024

Incidence of postoperative cytomegalovirus and BK-polyoma virus infections and graft loss in ABO-incompatible renal transplant recipients: a multicenter retrospective study.

Incidence of postoperative cytomegalovirus and BK-polyoma virus infections and graft loss in ABO-incompatible renal transplant recipients: a multicenter retrospective study.

Journal: International urology and nephrology

Published: November 06, 2023

Impact of timing of rejection episode on cardiovascular events in living donor kidney transplantation: a multicenter retrospective study.

Impact of timing of rejection episode on cardiovascular events in living donor kidney transplantation: a multicenter retrospective study.

Journal: Journal of nephrology

Published: August 17, 2023

Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.

Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.

Journal: International journal of clinical oncology

Published: April 01, 2022

Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.

Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.

Journal: World journal of urology

Published: November 17, 2021

Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan.

Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan.

Journal: Medical oncology (Northwood, London, England)

Published: November 13, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026